IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Meridian Bioscience, Inc. (“Meridian” or the “Company”) (Nasdaq: VIVO) concerning possible violations of federal securities laws.
“due to customer buying patterns and general weakness overall.”
If you purchased shares of Meridian, and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
On January 25, 2017, Meridian disclosed poor first-quarter 2017 fiscal year ("1Q 2017") financial results, changed its formerly issued revenue forecast for the 2017 fiscal year downwards, and noted that the Board of Directors reduced the annual indicated dividend rate. John A. Kraeutler, Chief Executive Officer, attributed the negative quarterly outcome to revenue decreases in Meridian's Americas diagnostic company, Meridian's largest profit driver, across all major product categories, "due to customer buying patterns and general weakness overall."
When this information was revealed to the public, the value of Meridian stock fell, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.